Retraction of six ARVO Annual Meeting abstracts:
“Effect of 3-Hour Normobaric Hyperoxia on Diabetic Macular Edema” by Robert Minturn, Brendan Seto, Keiko Yamada, Ke Zeng, and Jorge G. Arroyo (Invest Ophthalmol Vis Sci. 2019;60(9):2635).
“The Effect of Hyperoxia and Hypercapnia on Retinal Vascular Blood Flow in Healthy Adults” by Keiko Yamada, Brendan Seto, Christopher Llerena, Christopher Hsu, Chie Sotozono, Takatoshi Maeno, and Jorge G. Arroyo (Invest Ophthalmol Vis Sci. 2019;60(9):5742).
“Human Laser Speckle Retinal Blood Flow Changes Associate with Exposure to Varying Concentrations of O2 and CO2” by Keiko Yamada, Rachelle Koch, Purva Atreay, Sinjin Swartz, Takatoshi Maeno, Chie Sotozono, Brendan Seto, and Jorge G. Arroyo (Invest Ophthalmol Vis Sci. 2020;61(7):1749).
“Short-Term Normobaric Hyperoxia Treatment for Dry Age-Related Macular Degeneration: An Exploratory Study” by Justin Wang, Colin Lemire, Brendan Seto, Keiko Yamada, and Jorge G. Arroyo (Invest Ophthalmol Vis Sci. 2021;62(8):312).
“Anatomical and Physiological Effects of Nocturnal Normobaric Hyperoxia Treatment in Patients with Diabetic Macular Edema” by Soobin Song, Colin Lemire, Purva Atreay, Brendan Seto, Keiko Yamada, and Jorge G. Arroyo (Invest Ophthalmol Vis Sci. 2021;62(8):1069).
“Assessing Clinical and Anatomical Outcomes for Central Serous Chorioretinopathy Treated With Standard of Care or Experimental Hyperoxia” by Mortada Salman Najem, Colin Lemire, Abigail Ralph, Brendan Seto, Keiko Yamada, and Jorge G. Arroyo (Invest Ophthalmol Vis Sci. 2021;62(8):3105).
After the research outlined in the above abstracts was presented at the ARVO Annual Meetings, and after the abstracts were published in IOVS, a serious issue related to lack of Institutional Review Board (IRB) approval for the research procedures was brought to the attention of the journal by the IRB, and has been corroborated by the corresponding author. It was therefore agreed that the abstracts should be retracted from the journal.